Vasculitis and Giant Cell Arteritis News

The largest dataset of U.S. patients with Behçet’s disease to date shows that nearly 80% are women, according to researchers who published their findings in Arthritis Research & Therapy.

Although immunosuppressives remain the cornerstone for managing underlying interstitial lung disease in connective tissue diseases, new drug approvals could help shift the treatment paradigm, according to data presented here.

Cancer screening recommendations for patients with autoimmune diseases largely rely on clinical experience and extrapolation in the absence of abundant data, according to a speaker at the 2021 Congress of Clinical Rheumatology-East meeting.

So-called “COVID toes” and other cutaneous manifestations of the virus are not the only dermatologic challenges that a rheumatologist may face, according to a presenter at the 2021 Congress of Clinical Rheumatology-East.

More thorough understanding of giant cell arteritis disease processes has shed light on how immune checkpoint inhibitors may be exacerbating this and other immune-mediated conditions, according to a presenter here.

In this Healio Video Perspective from the Congress of Clinical Rheumatology – East Annual Symposium, Cornelia Weyand, MD, PhD, professor of medicine and immunology at Mayo College of Medicine, professor of medicine at Stanford University School of Medicine and director of the Program in Immunity and Inflammation at Mayo Clinic, discusses the immune pathogenesis of vasculitis and how the pandemic has changed the understanding of the immune system.

This past spring, two studies shed light on how some of the largest clinician organizations and publishers in rheumatology, including the American College of Rheumatology and EULAR, have failed to provide adequate training materials or clear guidelines when it comes to caring for patients of color.

There is no evidence that recovery from multisystem inflammatory syndrome in children differs following treatment with glucocorticoids alone, intravenous immune globulin alone or a combination of the two, according to data.

Sofosbuvir, mirabegron and nintedanib — all approved within the past 9 years — are among the drugs associated with the highest disproportionate reporting of ANCA-associated vasculitis, according to data.

The American College of Rheumatology has released three new vasculitis treatment guidelines — for ANCA-associated vasculitis, giant cell arteritis and Takayasu arteritis, and polyarteritis nodosa — with a fourth expected soon.